Wall Street analysts are making notable moves with their latest stock recommendations, signaling shifts investors should watch closely. These top research calls reflect both optimism for select stocks and cautious reevaluation of others amid changing market dynamics.
Top Upgrades Reflect Confidence Amid Volatility
Wedbush upgraded Carvana (CVNA) to Outperform from Neutral, raising the price target to $400. The firm views the recent share pullback as excessive and encourages investors to capitalize on current weakness.
Bank of America boosted Booking Holdings (BKNG) to Buy from Neutral, maintaining a $6,000 price target. The firm dismisses fears about Google’s and OpenAI’s impact on Booking, calling current AI-related selloffs a buying opportunity.
HSBC upgraded Flutter Entertainment (FLUT) to Buy from Hold, setting a $228 target despite a reduction from $265. The downgrade in price target follows a recent selloff, yet HSBC sees value in the shares.
Wolfe Research raised Morgan Stanley (MS) to Outperform from Peer Perform with a $198 price target. Faster revenue growth driven by increased share in investment banking and wealth management underpins the positive outlook.
Wells Fargo upgraded Merck (MRK) to Overweight from Equal Weight, increasing the target to $125. Recent advancements in pipeline and launches support expectations for revenue growth, especially after Keytruda’s loss of exclusivity.
Downgrades Signal Caution and Valuation Concerns
UBS downgraded JFrog (FROG) to Neutral from Buy with a higher price target of $65. While AI-related drivers matter, UBS notes sizable revenue gains likely remain 12-18 months ahead, and current valuation already reflects optimism.
Jefferies lowered Exact Sciences (EXAS) to Hold from Buy, raising the target to $105 amid its acquisition by Abbott. The firm views the takeover premium as fairly priced and doubts a rival bid will emerge.
Evercore ISI reduced QuantumScape (QS) from Outperform to In Line, increasing the price target to $12. Despite the strong stock rally—up 200% year-to-date—valuation concerns prompted the downgrade.
UBS also downgraded Jazz Pharmaceuticals (JAZZ) to Neutral from Buy, raising the target to $188. Following a strong Phase 3 trial and a 25% stock rally, UBS believes the stock is fairly valued with balanced risk and reward.
TD Cowen cut PureCycle Technologies (PCT) to Hold from Buy, lowering its price target to $9 due to delayed orders. The firm prefers to wait as the company works to demonstrate its growth and profitability claims.
These research updates highlight Wall Street’s nuanced perspectives, balancing growth potential with valuation and competitive risks. Investors should monitor these calls to navigate shifting opportunities and challenges in today’s market.
Read more at: finance.yahoo.com
